

Contents

<i>Preface</i>	<i>vii</i>
<i>Syllabus</i>	<i>ix</i>

1. Pharmaceutical Documentation and Regulatory Submissions and Product Approval Requirements	1
➤ Documentation in Pharmaceutical Industry	1
» Introduction to Pharmaceutical Documentation	1
» Key Documents in the Pharmaceutical Industry	2
» Development of Generic Drugs.....	5
» The Hatch-Waxman Act: A Regulatory Milestone	10
» Code of Federal Regulations (CFR) in Drug Performance Evaluation	14
» ANDA and NDA: Regulatory Approval Pathways.....	21
» Bioequivalence and Drug Product Assessment	29
» Scale-Up, Post-Marketing Surveillance, and Regulatory Changes.....	34
» Outsourcing BA/BE Studies to CROs	39
➤ Regulatory Requirements for Product Approvals	43
» Active Pharmaceutical Ingredients (APIs).....	43
» Biologics.....	46
» Novel Therapies	51
» NDA Process.....	57
» ANDA Process	60
» Registering Foreign Drugs in the U.S. Market	65
» Strategies for Market Entry	65
» Appointment of a U.S. Agent.....	66
» Submission of Regulatory Documentation: NDA, ANDA, or DMF	66
» Compliance with FDA Facility Inspections	67
» Compliance with GMP and Regulatory Requirements.....	68
» Post-Market Surveillance and Pharmacovigilance.....	69
» Regulatory Requirements	70
<i>Review Questions</i>	<i>75</i>
2. CMC and Post-Approval Regulatory Affairs	76
» Introduction to Chemistry, Manufacturing, and Controls (CMC).....	76
» Regulatory Requirements for Combination Products and Medical Devices	82
» Introduction to the Common Technical Document (CTD) and Electronic CTD (eCTD)	88
» Role of Industry Stakeholders and FDA Liaison in Regulatory Processes	95

» Overview of ICH Guidelines: ICH-Q, ICH-S, and ICH-E/M	100
» Global Regulatory Submission Requirements	104
<i>Review Questions</i>	109
3. Non-Clinical Drug Development.....	111
» Investigational New Drug (IND) Application	111
» New Drug Application (NDA).....	112
» Abbreviated New Drug Application (ANDA)	114
➤ Preparation and Review of Regulatory Dossiers and Drug Product Documentation.....	115
» Regulatory Dossiers: Purpose and Importance	115
» Components of a Regulatory Dossier	116
» Preparing the Regulatory Dossier.....	117
» Reviewing the Regulatory Dossier.....	118
» Finalizing and Submitting the Dossier	119
➤ Detailed Investigation and Compilation of the Investigational Medicinal Product Dossier (IMPD) and the Investigator's Brochure (IB), Essential for Non-Clinical Submissions	120
» Introduction.....	120
» Overview of the Investigational Medicinal Product Dossier (IMPD)	121
» Overview of the Investigator's Brochure (IB).....	122
» Preparing the Investigational Medicinal Product Dossier (IMPD).....	124
» Preparing the Investigator's Brochure (IB)	125
» The Role of IMPD and IB in Non-Clinical Submissions.....	125
<i>Review Questions</i>	126
4. Clinical Trials	127
» Design and Development of Clinical Trial Protocols	127
» Functions and Responsibilities of Institutional Review Boards (IRBs) and Independent Ethics Committees (IECs)	129
» Drafting and Following Standard Operating Procedures (SOPs) for Clinical Trials	130
» Informed Consent Processes and Legal/Ethical Considerations.....	131
» HIPAA (Health Insurance Portability and Accountability Act) Requirements and Their Relevance to Clinical Study Management.....	132
» Monitoring Pharmacovigilance and Safety Throughout the Trial Duration, Including Adverse Event Reporting and Data Monitoring Practices	134
<i>Review Questions</i>	137